More than 200 people in nine states have reported bleeding or other symptoms associated with exposure to synthetic cannabinoid products containing an anticoagulant agent, including five who died, the Centers for Disease Control and Prevention reported Friday in an update on an outbreak that began in March. Most of the cases were in Illinois, and the rest in Maryland, Florida, Indiana, Kentucky, Missouri, Pennsylvania, Virginia and Wisconsin. Nearly all of the patients have tested positive for brodifacoum, a vitamin K antagonist anticoagulant, which public health officials believe may have been mixed with synthetic cannabinoid products, commonly referred to as synthetic marijuana, K2 or Spice. CDC said health care providers should screen patients presenting with unexplained bleeding and a possible history of synthetic cannabinoid for vitamin K-dependent antagonist coagulopathy, and report possible cases to their local health department, among other recommendations.

Related News Articles

Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response will provide $23 million for Merck to produce…
Headline
Patients receiving either of two investigational treatments for Ebola in the Democratic Republic of the Congo had a greater chance of survival than those…
Headline
The Department of Health and Human Services offers a resource to help health care providers and others prepare for and respond to mass violence events such as…
Headline
The state of Florida and city of Philadelphia each declared public health emergencies last week to address hepatitis A outbreaks.
Headline
The number of naloxone prescriptions dispensed from retail pharmacies doubled in 2018, but access to the emergency opioid overdose treatment still varies…
Headline
Hospitals treated dozens of victims from mass shootings this weekend at a Walmart in El Paso, Texas, and hours later in downtown Dayton, Ohio, which together…